OPEN END TURBO BULL - MODERNA | Market Closed - Deutsche Boerse AG 01:41:29 2024-07-12 pm EDT | ||
| 4.02 EUR | -0.25% |
|
| Current month | +9.24% | ||
| 1 month | -38.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.02 | -0.25% |
| 24-07-11 | 4.03 | +6.61% |
| 24-07-10 | 3.78 | +8.93% |
| 24-07-09 | 3.47 | -0.86% |
| 24-07-08 | 3.5 | +1.16% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 01:41 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Citi
|
| WKN | KJ104Z |
| ISIN | DE000KJ104Z5 |
| Date issued | 2023-12-14 |
| Strike | 80.32 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.38 € |
|---|---|
| Lowest since issue | 0.37 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.12%
- Stock Market
- Certificates
- Certificat
